N/A
N=31
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression
Major Depressive Disorder
Bottom Line
View on ClinicalTrials.gov: NCT02176408 ↗Enrolled (actual)
31
Serious AEs
9.7%
Results posted
Sep 2019
Primary outcome: Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 11.2; 16.0 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Behavioral Activation (Behavioral); Exercise Intervention (Behavioral); Stretching Intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boston University Charles River Campus
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Montgomery-Asberg Depression Rating Scale (MADRS) |
11.2; 16.0 | — |
| SECONDARY Beck Depression Inventory-II (BDI-II) |
8.7; 13.2 | — |
| SECONDARY Work and Social Adjustment Scale (WSAS) |
10.7; 16.5 | — |
| SECONDARY Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) |
53.9; 45.5 | — |
| SECONDARY Logical Memory |
34.75; 28.18 | — |
| SECONDARY Continuous Performance Test- Identical Pairs |
2.99; 3.05 | — |
| SECONDARY 7 Day Physical Activity Recall (PAR) |
752.89; 530.00 | — |
| SECONDARY Brain-derived Neurotrophic Factor (BDNF) |
25996.86; 26601.11 | — |
Summary
Major depressive disorder (MDD) is the leading cause of disability in the developed world and is associated with lost productivity, increased health care utilization, and mortality. Several empirically supported treatments, such as antidepressant medication and cognitive behavioral therapy, exist for the treatment of MDD; however, studies have shown that as many as 34% of individuals do not respond to these treatments. Exercise and stretching interventions represent alternative strategies associated with strong effect sizes in past studies. Additionally, exercise has been shown to enhance cognitive functioning, especially attention and memory. This study aims to investigate the effect of a combined aerobic exercise and behavioral activation treatment (BA) for MDD. Behavioral activation treatment involves completing both pleasant and mastery-based activities with the goal of enhancing mood. The current study will recruit 32 MDD patients for an active treatment phase of nine 60-90 minute sessions (6 weekly sessions and 3 biweekly sessions) of either BA plus exercise (BA+EX) or BA plus stretching (BA+STR). The purpose of this study is to identify if adding aerobic exercise to a brief psychosocial treatment can improve mood above and beyond an active control condition.
Eligibility Criteria
Inclusion Criteria
- Males and females ages 18-65 with a principal DSM-5 diagnosis of MDD or Persistent Depressive Disorder with a current Major Depressive Episode (as determined by the Anxiety and Related Disorders Interview Schedule-5)
- Sedentary (moderate-intensity exercise less than two days per week for at least 30 minutes each time for at least 3 months)
- Able to provide informed consent for the study
- Sufficient command of the English language
Exclusion Criteria
- Current or past psychotic disorders of any type, bipolar disorder (I, II, or NOS), schizophrenia or schizoaffective disorder, anorexia, bulimia, or alcohol or drug dependence
- Currently suicidal or high suicide risk (as evaluated by the Columbia Suicide Severity Rating Scale and BDI suicide item)
- Risk for exercise according to the Physical Activity Readiness Questionnaire (PAR-Q) in accordance with the guidelines set forth by the American College of Sports Medicine (ACSM) (i.e., existence of the conditions in the next bullet point)
- Physical conditions (e.g., heart conditions, diabetes, asthma or another lung disease, bone/joint problems, or seizure disorder) interfering with the ability to exercise safely
- Individuals who have participated in cognitive behavioral therapy (CBT) directed towards the treatment of a mood disorder within three months of baseline, those simultaneously participating in another psychosocial treatment (other than supportive therapy) or those not currently stable (i.e., same dosage for at least 8 weeks) on psychotropic medications
- Women who are currently pregnant, plan to be pregnant in the next year, or currently breastfeeding
Data sourced from ClinicalTrials.gov (NCT02176408). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.